In people with asthma ages 12 years and older, clinical trials showed that Dupixent helped prevent severe asthma attacks
. It improved people’s breathing, and they didn’t have to use oral corticosteroids as often to relieve asthma symptoms. Oral corticosteroids are medications such as prednisone that are used to treat inflammation.Chronic rhinosinusitis with nasal polyps
In a 24-week clinical trial, people taking Dupixent saw about a 51% to 59% improvement in nasal congestion. This is compared to a 16% to 18% improvement in people taking a placebo (a treatment without an active drug). Also, 52% of people saw improvement in their sense of smell. Reduced ability to smell is a common side effect of nasal polyps.FDA Approval
Dupixent was first approved by the Food and Drug Administration (FDA) in 2017 to treat eczema in adults.
In 2018, it was approved as an add-on maintenance therapy to treat moderate to severe asthma that’s classified as eosinophilic or corticosteroid-dependent in adults and in children ages 12 years and older.
In 2019, Dupixent was approved to treat moderate to severe eczema in children ages 12 years and older with symptoms that can’t be controlled by topical prescriptions (or when topical treatments should not be used). Also in 2019, Dupixent was approved as add-on maintenance therapy to treat chronic rhinosinusitis with nasal polyps in adults.